News Releases

Date Title and Summary Additional Formats
Toggle Summary AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Acquisition Includes TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease  Tavneos Adds to Amgen 's Decades-Long Leadership in Inflammation and Nephrology THOUSAND OAKS, Calif. and SAN CARLOS, Calif. , Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and
View HTML
Toggle Summary ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
SAN CARLOS, Calif. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
-- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board -- SAN CARLOS, Calif. , July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an
View HTML
Toggle Summary ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif.
View HTML
Toggle Summary ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
SAN CARLOS, Calif. , May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS ® (avacopan), an orally administered selective complement 5a receptor (C5aR)
View HTML
Toggle Summary ChemoCentryx Announces Changes to its Board of Directors
-- David E. Wheadon , M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell , Jr., to Retire from Board -- SAN CARLOS, Calif. , May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced changes to the composition of its Board of Directors.
View HTML
Toggle Summary ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
-- Supports plans to advance TAVNEOS ® (avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif. , May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that a poster
View HTML
Toggle Summary ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
SAN CARLOS, Calif. , May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET .
View HTML
Toggle Summary ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
SAN CARLOS, Calif. , May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS ® (avacopan), an orally
View HTML
Toggle Summary ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
-- Five-fold increase in net sales of TAVNEOS ® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique Prescribers - 308% Patients on Drug -- -- Global
View HTML